- Patients with chronic migraine treated with IV eptinezumab reported about a 50% decrease in monthly migraine days (MMDs) during a 12-week period, a significantly greater decrease compared with patients who received a placebo.
- The preventative effects from eptinezumab were reported as early as 1 day after treatment.
Why this matters
- Patients with migraine report the speed of preventive benefit as a primary concern of treatment.
- PROMISE-2, phase 3, multicenter, randomized double-blind, placebo-controlled, parallel-group study of 1121 patients (age range, 18-65 years) with migraine who were randomly assigned (1:1:1) to receive eptinezumab 100 mg, eptinezumab 300 mg, or placebo.
- Outcome: reduction in MMDs.
- Funding: H. Lundbeck A/S, Copenhagen, Denmark.
- Over 12-week duration, treatment with eptinezumab 100 and 300 mg vs placebo:
- Reduced mean MMDs: −7.7 and −8.2 vs −5.6 (P<.0001>
- Achieved ≥50% migraine responder rate: 57.6% and 61.4% vs 39.3% (P<.0001>
- Self-reported data.
Coauthored with Vijay Rathod PhD